16480-05-0

Basic information

• Product Name: CYCLOPROPANECARBONYL CHLORIDE,1-METHYL-
• Synonyms: CYCLOPROPANECARBONYL CHLORIDE,1-METHYL-;1-Methylcyclopropanecarbonyl chloride;1-methylcyclopropane-1-carbonyl chloride
• CAS NO: 16480-05-0
• Molecular Formula: C₅H₇ClO
• Molecular Weight: 118.56
• Mol File: 16480-05-0.mol

Chemical Properties

• Boiling Point: 108.3±9.0 °C(Predicted)
• Appearance: /
• Density: 1.212±0.06 g/cm3(Predicted)
• CAS DataBase Reference: CYCLOPROPANECARBONYL CHLORIDE,1-METHYL-(CAS DataBase Reference)
• NIST Chemistry Reference: CYCLOPROPANECARBONYL CHLORIDE,1-METHYL-(16480-05-0)
• EPA Substance Registry System: CYCLOPROPANECARBONYL CHLORIDE,1-METHYL-(16480-05-0)

Safety Data

• RIDADR: UN3265
• Hazardous Substances Data: 16480-05-0(Hazardous Substances Data)

Upstream product

• 6914-76-7 1-Methyl-cyclopropanoic acid 
• 79-37-8 oxalyl dichloride 
• 71441-76-4 1-methylcyclopropanecarboxylic acid ethyl ester 
• 1346641-14-2 C₉H₁₆O₂ 
• 78104-88-8 1-Methylcyclopropancarbonsaeurenitril 

Downstream Products

• 70338-48-6 4'-(Benzyloxy)-3'-trifluoromethyl-1-methylcyclopropanecarboxanilide 
• 70338-46-4 4'-(isopropoxy)-3'-(trifluoromethyl)-1-methylcyclopropanecarboxanilide 
• 70338-51-1 4'-(cyclopropylmethoxy)-3'-(trifluoromethyl)-1-methylcyclopropanecarboxanilide 
• 792844-26-9 C₂₂H₂₉NO₅ 
• 70338-59-9 1-Methyl-cyclopropanecarboxylic acid (4-methoxy-3-trifluoromethyl-phenyl)-amide 
• 70338-60-2 1-Methyl-cyclopropanecarboxylic acid (4-ethoxy-3-trifluoromethyl-phenyl)-amide 
• 70339-03-6 4'-(isopropoxy)-3'-chloro-1-methylcyclopropanecarboxanilide 
• 70338-97-5 4'-(cyclopropylmethoxy)-3'-chloro-1-methylcyclopropanecarboxanilide 
• 70338-95-3 1-Methyl-cyclopropanecarboxylic acid (4-isopropoxy-3-nitro-phenyl)-amide 
• 70338-98-6 1-Methyl-cyclopropanecarboxylic acid (4-benzyloxy-3-chloro-phenyl)-amide 
• 70339-05-8 1-Methyl-cyclopropanecarboxylic acid [3-chloro-4-(1-cyclopropyl-ethoxy)-phenyl]-amide 
• 70338-62-4 1-Methyl-cyclopropanecarboxylic acid (4-allyloxy-3-trifluoromethyl-phenyl)-amide 
• 70338-65-7 1-Methyl-cyclopropanecarboxylic acid (4-butoxy-3-trifluoromethyl-phenyl)-amide 
• 70338-64-6 4'-(isobutoxy)-3'-(trifluoromethyl)-1-methylcyclopropanecarboxanilide 

Relevant articles and documents

Synthesis and spectral properties of cyclopropyl-substituted phosphaalkenes

Cyclopropanecarboxylic acid chlorides 5a-d react with tris(trimethylsilyl)phosphane 6 in benzene at -2 deg C to form cyclopropylcarbonyl-bis(trimethylsilyl)phosphanes 7.These products undergo silylic rearrangement at 25 deg C to yield phosphoalkenes 8.Compounds 8a,b,d are formed as mixtures of Z- and E-isomers where the latter predominante.In the case of 8c, the Z-isomer is formed exclusively. - Key words: phosphaalkenes, cyclopropyl-substituted, E/Z-isomerism.

σ-Bond Hydroboration of Cyclopropanes

Hydroboration of alkenes is a classical reaction in organic synthesis in which alkenes react with boranes to give alkylboranes with subsequent oxidation resulting in alcohols. The double bond (π-bond) of alkenes can be readily reacted with boranes owing to its high reactivity. However, the single bond (σ-bond) of alkanes has never been reacted. To pursue the development of σ-bond cleavage, we selected cyclopropanes as model substrates since they present a relatively weak σ-bond. Herein, we describe an iridium-catalyzed hydroboration of cyclopropanes, resulting in β-methyl alkylboronates. These unusually branched boronates can be derivatized by oxidation or cross-coupling chemistry, accessing "designer"products that are desired by practitioners of natural product synthesis and medicinal chemistry. Furthermore, mechanistic investigations and theoretical studies revealed the enabling role of the catalyst.

SUBSTITUTED 2-AMINO-PYRAZOLYL-[1,2,4]TRIAZOLO[1,5A] PYRIDINE DERIVATIVES AND USE THEREOF

Provided herein are 2-amino-pyrazolyl-[ 1,2,4]triazolo [1,5a]pyridine derivatives. Such compounds are useful, for example, for the treatment and/or prevention of neurodegenerative diseases or disorders such as ophthalmological neurodegenerative disorders. This disclosure also features compositions containing the same as well as methods of using and making the same.

BENZETHERS AND ANILINES OF PYRAZOLYL-AMINO-PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF

Provided is a novel class of orally and/or topically available, selective and potent JAK inhibitors as safe and effective therapeutics against various diseases and disorders. Also provided is pharmaceutical composition of these compounds and methods of th

Pd/Cu-Catalyzed Cascade C(sp3)-H Arylation and Intramolecular C-N Coupling: A One-Pot Synthesis of 3,4-2 H-Quinolinone Skeletons

In this letter, we successfully explored a cascade Pd/Cu-catalyzed intermolecular C(sp3)-H arylation of amides and intramolecular C-N coupling reaction. This method provides a one-pot strategy to synthesize 3,4-2H-quinolinone with good regioselectivity of C-H arylation and C-N coupling from C-I and C-X bonds from readily available starting materials.

Discovery of β-Arrestin Biased, Orally Bioavailable, and CNS Penetrant Neurotensin Receptor 1 (NTR1) Allosteric Modulators

Neurotensin receptor 1 (NTR1) is a G protein coupled receptor that is widely expressed throughout the central nervous system where it acts as a neuromodulator. Neurotensin receptors have been implicated in a wide variety of CNS disorders, but despite extensive efforts to develop small molecule ligands there are few reports of such compounds. Herein we describe the optimization of a quinazoline based lead to give 18 (SBI-553), a potent and brain penetrant NTR1 allosteric modulator.

COMBINATION TREATMENTS COMPRISING IMIDAZOPYRAZINONES FOR THE TREATMENT OF PSYCHIATRIC AND/OR COGNITIVE DISORDERS

The present invention provides combination treatments comprising administration of compounds that are PDE1 enzyme inhibitors and other compounds useful in the treatment of psychiatric and/or cognitive disorders such as for example Attention Deficit Hyperactivity Disorder (ADHD), depression, anxiety, narcolepsy, schizophrenia, cognitive impairment or cognitive impairment associated with schizophrenia (CIAS). Separate aspects of the invention are directed to the combined use of said compounds for the treatment of psychiatric and/or cognitive disorders. The present invention also provides pharmaceutical compositions comprising said PDE1 enzyme inhibitors together with other compounds useful in the treatment of psychiatric and/or cognitive disorders.

COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF IMIDAZOPYRAZINONES

The present invention provides combination treatments comprising administration of compounds that are PDE1 enzyme inhibitors and other compounds useful in the treatment of neurodegenerative disorders such as for example Alzheimer's Disease, Parkinson's Disease or Huntington's Disease. Separate aspects of the invention are directed to the combined use of said compounds for the treatment of neurodegenerative and/or cognitive disorders. The present invention also provides pharmaceutical compositions comprising said PDE1 enzyme inhibitors together with other compounds useful in the treatment of neurodegenerative disorders.

Synthesis and biological evaluation of new berberine derivatives as cancer immunotherapy agents through targeting IDO1

To discover small-molecule cancer immunotherapy candidates through targeting Indoleamine 2,3-dioxygenase 1 (IDO1), twenty–five new berberine (BBR) derivatives defined with substituents on position 3 or 9 were synthesized and examined for repression of IFN-γ-induced IDO1 promoter activities. Structure–activity relationship (SAR) indicated that large volume groups at the 9-position might be beneficial for potency. Among them, compounds 2f, 2i, 2n, 2o and 8b exhibited increased activities, with inhibition rate of 71–90% compared with BBR. Their effects on IDO1 expression were further confirmed by protein level as well. Furthermore, compounds 2i and 2n exhibited anticancer activity by enhancing the specific lysis of NK cells to A549 through IDO1, but not cytotoxicity. Preliminary mechanism revealed that both of them inhibited IFN-γ-induced IDO1 expression through activating AMPK and subsequent inhibition of STAT1 phosphorylation. Therefore, compounds 2i and 2n have been selected as IDO1 modulators for small-molecule cancer immunotherapy for next investigation.

BENZOAZEPINE ANALOGS AS INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE

Provided are compounds of Formula (I), or pharmaceutically acceptable salts thereof, and methods for their production and compounds of formula (I) for use in treating a disease responsive to the inhibition of Bruton's tyrosine.